logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Clinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis | Journal Article / Commentary | MSF Science Portal
Journal Article
|Commentary

Clinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis

Conradie F, Meintjes GA, Hughes J, Maartens G, Ferreira H, Siwendu S, Master I, Ndjeka N
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
While clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme

Countries

South Africa

Subject Area

antibiotic resistancetuberculosisantimicrobial resistanceaccess to health care

Languages

English
DOI
10.7196/samj.7263
Published Date
01 Mar 2014
Journal
South African Medical Journal
Volume | Issue | Pages
Volume 104, Issue 3
Issue Date
2014-02-06
Dimensions Badge